Stoke Therapeutics, Inc. (STOK) intrinsic value & 10-year financials
Stoke Therapeutics, Inc. (STOK) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 9 fiscal years revenue grew 145.9% a year to $184.4M, with an average return on invested capital of 430.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $24.17
- Market cap
- $1.4B
- Revenue (FY2025)
- $184.4M
- Revenue growth (9-yr CAGR)
- 145.9%
- ROIC (10-yr avg)
- 430.8%
- Free cash flow (FY2025)
- $44.9M
STOK 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $184.4M | -$6.9M | -$0.12 | $44.9M | -11.2% | -11.0% |
| FY2024 | $36.6M | -$89.0M | -$1.65 | -$87.1M | -277.3% | -233.0% |
| FY2023 | $8.8M | -$104.7M | -$2.38 | -$82.7M | -1307.2% | -446.4% |
| FY2022 | $12.4M | -$101.1M | -$2.60 | -$35.8M | -841.2% | -134.4% |
| FY2021 | — | -$85.8M | -$2.34 | -$68.1M | — | -228.0% |
| FY2020 | — | -$52.2M | — | -$43.3M | — | 4542.9% |
| FY2019 | — | -$32.3M | — | -$32.7M | — | -19.6% |
| FY2018 | — | -$12.5M | — | -$11.9M | — | -24.1% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Stoke Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Stoke Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -19.1% ROIC.
Stoke Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Stoke Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-3.99 per share.